Vaxcyte, Inc.
PCVX
$33.02
-$0.93-2.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -509.63M | -463.93M | -507.65M | -497.19M | -436.82M |
| Total Depreciation and Amortization | 17.63M | 15.85M | 14.01M | 12.00M | 10.92M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 62.80M | 50.35M | 37.95M | 27.89M | 16.97M |
| Change in Net Operating Assets | -30.58M | -54.90M | -14.35M | -9.57M | 715.00K |
| Cash from Operations | -459.78M | -452.63M | -470.04M | -466.88M | -408.22M |
| Capital Expenditure | -133.84M | -119.16M | -146.20M | -115.46M | -74.34M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.30B | -1.89B | -1.32B | -407.67M | -701.94M |
| Cash from Investing | -1.43B | -2.01B | -1.46B | -523.13M | -776.28M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.65B | 2.46B | 2.46B | 986.66M | 1.42B |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.28M | -14.29M | -13.54M | -6.81M | -6.46M |
| Cash from Financing | 1.63B | 2.45B | 2.45B | 979.85M | 1.42B |
| Foreign Exchange rate Adjustments | -4.46M | 426.00K | -8.61M | -1.98M | -647.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -264.45M | -9.36M | 505.27M | -12.13M | 231.29M |